Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-MSLN Polyclonal Antibody

Catalog #:   PHG52001 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: Q13421
Overview

Catalog No.

PHG52001

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human MSLN (Glu296-Ser598).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

CAK1 antigen,Mesothelin,MSLN,Pre-pro-megakaryocyte-potentiating factor,MPF

Purification

Purified by antigen affinity column.

Accession

Q13421

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • WESTERN BLOT
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with MSLN antibody (PHG52001) at 1 μg/ml.

    Lane 1: Recombinant protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 36 kDa
    Observed MW: 36 kDa
  • Immunocytochemistry/ Immunofluorescence
    MSLN in Hela Cell Line.
    The Hela cells were fixed with 4% paraformaldehyde (20 min), and then blocked with 5% goat serum for 1h. And the cells were incubated for 2h at 37°C with MSLN (PHG52001) at 9.2 μg/ml. The section was then incubated with Goat Anti-Rabbit IgG (Alexa Fluor-488) preabsorbed at 1/100 dilution (Shown in green) for 1 hour at room temperature.Nuclear DNA was labelled with DAPI (shown in blue).
References

Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances., PMID:40515614

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment., PMID:40514426

Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266

[Preliminary study of mesothelin-loaded paclitaxel nanoparticles for ultrasound molecular imaging and treatment of ovarian cancer]., PMID:40375590

Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma., PMID:40362535

Generating potent and persistent antitumor immunity via affinity-tuned CAR-T cells targeting mesothelin., PMID:40341217

Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells., PMID:40341026

Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation., PMID:40275270

Anti-Tumor Efficacy of a Mesothelin-Based Nanovaccine in a KPC Orthotopic Mouse Model of Pancreatic Cancer., PMID:40266223

Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin., PMID:40240561

Systemic therapy with the infectivity-selective oncolytic adenovirus by targeting mesothelin., PMID:40226846

Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies., PMID:40132909

Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager., PMID:40081946

Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies., PMID:40046734

Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer., PMID:39995672

Targeting Mesothelin Enhances Personalized Neoantigen Vaccine Induced Antitumor Immune Response in Orthotopic Pancreatic Cancer Mouse Models., PMID:39887656

Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography., PMID:39878895

Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)., PMID:39836408

A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity., PMID:39806351

Conditionally activated immunotoxins with prolonged half-life can enhance the anti-tumor activity., PMID:39603436

Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma., PMID:39542119

Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies., PMID:39431011

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors., PMID:39043602

T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin., PMID:38858494

A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin., PMID:38853444

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers., PMID:38706610

A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin., PMID:38647528

Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects., PMID:38641176

Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity., PMID:38349311

Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer., PMID:38319303

Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope., PMID:38227666

M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation., PMID:38091375

Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents., PMID:38027361

Ex vivo pleural effusion cultures to study chimeric antigen receptor T cell cytotoxicity in an immunocompetent environment., PMID:37875122

Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate., PMID:37771390

Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer., PMID:37612388

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin., PMID:37456982

Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies., PMID:37388728

NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumors., PMID:37146241

High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma., PMID:37040900

Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study., PMID:36564099

Pan-Cancer Analysis Identifies Tumor Cell Surface Targets for CAR-T Cell Therapies and Antibody Drug Conjugates., PMID:36428765

Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances., PMID:35961708

Immunotherapy targeting mesothelin in acute myeloid leukemia., PMID:35946307

Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer., PMID:35925286

Construction of a 124I-Labeled Specific Antibody for the Noninvasive Detection of Mesothelin-Overexpressing Tumors., PMID:35904514

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors., PMID:35902133

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy., PMID:35795680

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin., PMID:35512094

Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22., PMID:35464476

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-MSLN Polyclonal Antibody [PHG52001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only